{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:04Z","timestamp":1761897004659,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.leukres.2019.04.011","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T11:11:36Z","timestamp":1556104296000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-7443","authenticated-orcid":false,"given":"Petra","family":"Belohlavkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Steinerova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Skoumalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rohon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Indrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslava","family":"Voglova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Vrbacky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Cmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Necasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatuse","family":"Kristkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Zak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Papajik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3259-7791","authenticated-orcid":false,"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.leukres.2019.04.011_bib0005","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2019.04.011_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.011_bib0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2019.04.011_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"year":"2017","series-title":"Cancer Facts & Figures 2017","author":"American Cancer Society","key":"10.1016\/j.leukres.2019.04.011_bib0025"},{"issue":"June (12)","key":"10.1016\/j.leukres.2019.04.011_bib0030","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.011_bib0035","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2019.04.011_bib0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.leukres.2019.04.011_bib0045","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2019.04.011_bib0050","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.leukres.2014.06.020","article-title":"Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival","volume":"38","author":"Breccia","year":"2014","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.leukres.2019.04.011_bib0055","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2010.07.001","article-title":"\"Real-life\" results of front-line treatment with Imatinib in older patients (\u226565 years) with newly diagnosed chronic myelogenous leukemia","volume":"34","author":"Latagliata","year":"2010","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.011_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.011_bib0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2019.04.011_bib0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.leukres.2019.04.011_bib0075","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2019.04.011_bib0080","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2019.04.011_bib0085","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.011_bib0090","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.011_bib0095","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2019.04.011_bib0100","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL- positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2019.04.011_bib0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.011_bib0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hon.920","article-title":"Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose","volume":"28","author":"Breccia","year":"2010","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.011_bib0115","first-page":"1","article-title":"A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment","volume":"57","author":"Faber","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"35","key":"10.1016\/j.leukres.2019.04.011_bib0120","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2019.04.011_bib0125","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European Leukemia Net recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2019.04.011_bib0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.leukres.2019.04.011_bib0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"July (1)","key":"10.1016\/j.leukres.2019.04.011_bib0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2019.04.011_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.23330","article-title":"Long-term safety and efficacy of imatinib mesylate (Gleevec\u00ae) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study","volume":"88","author":"Rousselot","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.04.011_bib0150","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.leukres.2011.01.017","article-title":"Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study","volume":"35","author":"S\u00e1nchez-Guijoa","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.04.011_bib0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-016-2839-z","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2019.04.011_bib0160","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.04.011_bib0165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","article-title":"Large-scale imatinib dose \u2013concentration\u2013effect study in CML patients under routine care conditions","volume":"38","author":"Gotta","year":"2014","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2019.04.011_bib0170","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2019.04.011_bib0175","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00277-018-3413-7","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?","volume":"97","author":"Osorio","year":"2018","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.011_bib0180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clml.2011.10.001","article-title":"Considerations in the management of elderly patients with chronic myeloid leukemia","volume":"12","author":"Seiter","year":"2012","journal-title":"Clin. Lymph. Myeloma Leukemia"},{"issue":"March (3)","key":"10.1016\/j.leukres.2019.04.011_bib0185","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261930075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261930075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:13Z","timestamp":1758934813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261930075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"alternative-id":["S014521261930075X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.04.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}